Malignant pleural mesothelioma (MPM) is a lethal disease with poor prognosis. The
combination of cisplatin and pemetrexed has been confirmed as the standard of care for …

Malignant pleural mesothelioma (MPM) is associated with a poor prognosis. The
combination of cisplatin and pemetrexed has been established as a standard chemotherapy …

Purpose This multicenter, phase III study compared overall survival (OS) of second-line
pemetrexed plus best supportive care (BSC) versus BSC alone in patients with advanced …

The role of second-line therapy in patients with malignant pleural mesothelioma (MPM)
progressing after first-line pemetrexed-based chemotherapy (PBC) is currently undefined …

Background: The aim of this open label phase II study (NCT00407459) was to assess the
activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined …

Aims Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …

e18106 Background: The role of second-line therapy in MPM patients (pts) is currently
undefined. Recent case series have suggested a possible role of re-treatment PBC. Aim of …

Background In a randomized phase III trial, pemetrexed plus cisplatin was associated with
improved survival compared with cisplatin alone for patients with malignant pleural …

Background: Cisplatin-pemetrexed combination chemotherapy is the current standard
primary treatment for malignant pleural mesothelioma (MPM). It was first approved for …

18198 Introduction: Based on the study of Vogelzang (2003) standard treatment in patients
with malignant pleural mesothelioma (MPM) is pemetrexed cisplatin with a medium survival …